Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

2.

First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure.

Denis P, Baudouin C, Bron A, Nordmann JP, Renard JP, Rouland JF, Sellem E, Amrane M.

BMC Ophthalmol. 2010 Feb 24;10:4. doi: 10.1186/1471-2415-10-4.

3.

Latanoprost 0.005% test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma.

Allaire C, Dietrich A, Allmeier H, Grundmane I, Mazur-Piotrowska G, Neshev P, Kahle G.

Eur J Ophthalmol. 2012 Jan-Feb;22(1):19-27. doi: 10.5301/ejo.5000041.

PMID:
22167539
4.

Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.

Higginbotham EJ, Olander KW, Kim EE, Grunden JW, Kwok KK, Tressler CS; United States Fixed-Combination Study Group.

Arch Ophthalmol. 2010 Feb;128(2):165-72. doi: 10.1001/archophthalmol.2009.384.

PMID:
20142538
5.

A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.

Schachar RA, Raber S, Courtney R, Zhang M.

Curr Eye Res. 2011 Sep;36(9):809-17. doi: 10.3109/02713683.2011.593725.

PMID:
21851167
8.

A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.

Topouzis F, Melamed S, Danesh-Meyer H, Wells AP, Kozobolis V, Wieland H, Andrew R, Wells D.

Eur J Ophthalmol. 2007 Mar-Apr;17(2):183-90.

PMID:
17415690
9.
11.

Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension.

Zhao JL, Ge J, Li XX, Li YM, Sheng YH, Sun NX, Sun XH, Yao K, Zhong Z; Xalacom Study Group in China.

BMC Ophthalmol. 2011 Aug 19;11:23. doi: 10.1186/1471-2415-11-23.

12.
13.
14.

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.

Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL; VOYAGER study group.

Br J Ophthalmol. 2015 Jun;99(6):738-45. doi: 10.1136/bjophthalmol-2014-305908. Epub 2014 Dec 8.

15.

Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.

Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA; COSOPT versus XALATAN Study Groups.

Acta Ophthalmol Scand. 2004 Feb;82(1):42-8.

16.
17.

Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.

Stewart WC, Konstas AG, Nelson LA, Kruft B.

Ophthalmology. 2008 Jul;115(7):1117-1122.e1. Epub 2008 Feb 20.

PMID:
18082886
18.

Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.

Katz LJ, Rauchman SH, Cottingham AJ Jr, Simmons ST, Williams JM, Schiffman RM, Hollander DA.

Curr Med Res Opin. 2012 May;28(5):781-8. doi: 10.1185/03007995.2012.681036. Epub 2012 Apr 25.

PMID:
22458918
19.
20.

Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.

DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C.

Surv Ophthalmol. 2001 May;45 Suppl 4:S353-60.

PMID:
11434938

Supplemental Content

Support Center